ChemotherapyInvestigationalInvestigational
Platinum-based chemotherapy
How it works
Interferes with DNA replication, causing cancer cell death.
Cancer types
Prostate Cancer— All patients
Efficacy
Platinum-based chemotherapy is being investigated as a potential treatment for prostate cancer, but evidence is limited.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Rina-S Plus Standard Care for Ovarian Cancer Maintenance Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Comparing BL-B01D1 to Platinum-Based Chemotherapy for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Ovarian Cancer Study: Investigating INCB123667 vs Chemotherapy | Ovarian Cancer | phase-3 | — | Source → |
| Amivantamab Compared to Real-World Therapies in Lung Cancer Patients | Lung Cancer | phase-3 | Amivantamab-treated patients had significantly improved progression-free survival (median 6.9 vs. 2.3 months), time to next treatment (median 12.2 vs. 3.5 months), objective response rate (36.8% vs. 3.0%), and overall survival (median 23.1 vs. 7.5 months) compared to the adjusted external control group. | Source → |
| Study of Platinum in Treating Residual Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Surgery Benefits for Recurrent Ovarian Cancer Patients | Ovarian Cancer | observational | Complete macroscopic resection (R0) significantly improved survival across all surgeries, including secondary (36.6 vs. 15.3 months), tertiary (22.2 vs. 6.4 months), and quaternary (29.1 vs. 10.5 months). | Source → |
| Rare Lung Cancer Mutation Responds Poorly to Standard Treatment | Lung Cancer | observational | The median progression-free survival with first-line therapy was 7.4 months (95% CI: 3-12 months), and 9.8 months (95% CI: 3-27 months) for those receiving platinum-based chemotherapy in the first line. | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Platinum-based Chemotherapy in Ovarian Cancer Patients on PARP Inhibitors | Ovarian Cancer | observational | The objective response rate was 23.3%, and the disease control rate was 43.3%. | Source → |
| Predicting Response to Platinum-Based Chemotherapy in Ovarian Cancer | Ovarian Cancer | observational | The area under the curve (AUC) was 0.917 in the internal validation set, 0.877 in the external validation set using centre D, and 0.845 in the external validation set using centre E. | Source → |
| PARP Inhibitors Improve Survival in Ovarian Cancer Patients | Ovarian Cancer | observational | Median overall survival was 82.0 months in the PARPi group vs 44.7 months in the control group. | Source → |
| Predicting Lung Cancer Treatment Outcomes with PET/CT Scans | Lung Cancer | phase-2 | The clinical combined PET/CT radiomics model achieved areas under the curve of 0.832 and 0.833 for the training and test sets, respectively. | Source → |
| New Biomarkers for Detecting Platinum Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | Both EV CFH and EV TMEM205 exhibited excellent diagnostic capability for PR as noted by receiver operating characteristic curves with area under the curve values of 0.95 and 0.84, respectively. | Source → |
| Platinum-based chemotherapy rechallenge for ovarian cancer | Ovarian Cancer | observational | The disease control rate was 80% (95% CI: 61-92). | Source → |
| Predicting Ovarian Cancer Resistance to Platinum-Based Chemotherapy | Ovarian Cancer | lab-study | The model accurately predicted platinum resistance with an AUC of 0.964 (95% CI, 0.929-0.999). | Source → |
| New Treatment Options for Ovarian Cancer That Doesn't Respond to Platinum-Based Therapy | Ovarian Cancer | review | — | Source → |
| Germline Mutations Linked to Pancreatic Cancer Outcomes in Taiwanese Patients | Pancreatic Cancer | observational | Patients receiving 1L platinum-based chemotherapy exhibited a significantly longer median OS compared to those with platinum-free chemotherapy, 26.1 months versus 9.6 months. | Source → |
| Trabectedin's Role in Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
| Ovarian Cancer Cells Show Resistance to Platinum-Based Chemotherapy | Ovarian Cancer | lab-study | — | Source → |
| Ovarian Cancer Treatment Patterns in Argentina and Brazil | Ovarian Cancer | observational | — | Source → |
| REV7's role in pancreatic cancer treatment with platinum-based chemotherapy | Pancreatic Cancer | lab-study | REV7-deficient PDAC cell lines showed suppressed cell growth and enhanced sensitivity to cisplatin in vitro. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.